Telomeres consist of several thousand DNA repeats of *TTAGGG* in association with a protein complex at the ends of chromosomes in eukaryotic cells. Telomeres maintain chromosome integrity and genomic stability through prohibiting nucleolytic degradation, chromosomal end-to-end fusion and irregular recombination[@b1][@b2]. In humans, the average telomere length ranges from 10 to 15 kb[@b3], and telomeric DNA shortens during each cell replication at a rate of 50--200 bp[@b4]. In general, a critically short telomere length can trigger cell to enter replicative senescence with a result of cell death[@b5][@b6]; alternatively, cells continue to divide if death does not occur, which results in genomic instability and chromosomal abnormality. Therefore, telomere length acts as a mitotic clock for eukaryotic cells, and potentially represents the number of cell replications undertaken by each cell during its lifespan[@b7].

Telomeres are strongly correlated between tissues, and the rates of telomere shortening are also similar[@b8]. Telomere length in leukocytes is considered as useful surrogate for the other tissues. Numerous epidemiological studies have focused on analyzing the telomere length in peripheral blood cells in relation to various diseases, including multiple cancers. However, the reported findings are conflicting. In 2011, two meta-analysis[@b9][@b10] pooling more than 20 studies reported that the short telomeres were associated with increased cancer risk. They also found particularly strong evidence for bladder, esophageal, gastric, and renal cancers, but the study numbers were limited for each cancer type. Afterwards, emerging studies with relatively large sample size investigated the association between telomere length and cancer risk. However, the findings are still conflicting other than conclusive, particularly for different cancer types. Nevertheless, more and larger studies may allow for stronger statistical power for meta-analysis, especially for single cancer type. Herein, we carried out a systematic review and meta-analysis on 56 relevant literatures[@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47][@b48][@b49][@b50][@b51][@b52][@b53][@b54][@b55][@b56][@b57][@b58][@b59][@b60][@b61][@b62][@b63][@b64][@b65][@b66] to estimate the overall cancer risk or cancer-specific risk associated with telomere length and to evaluate potential between-study heterogeneity of these studies.

Materials and Methods
=====================

Search strategy and selection criteria
--------------------------------------

We conducted a literature review using PubMed to identify reports on an association between telomere length and cancer risk through to May 31, 2015. The search terms were "telomere length", "cancer" or "carcinoma", and "risk". We limited the publication language to English. The criteria included: 1) a case--control or cohort study design assessing the relationship between telomere length and cancer risk; 2) sufficient information for estimating odds ratios (ORs) and their 95% confidence intervals (CIs); 3) without overlap between studies in terms of study subjects.

Data extraction
---------------

The following data was extracted from each publication: the first author, year of publication, country, ethnicity, cancer type, the number of cases and controls grouped by median, tertiles, quartiles or quintiles of relative telomere length (T/S ratio), study design, DNA source, and method for telomere length measurement. Data was extracted separately for studies including subjects from different ethnicities, multiple cancer types or independent populations if possible. Because controls were shared for multiple cancers in two publications[@b11][@b47], each publication was divided into multiple studies in the cancer-specific analysis but treated as one study by pooling all cancer cases together as compared with shared controls. When multiple publications had the same or overlapping subjects, only the largest or latest studies were included.

Quantitative data synthesis
---------------------------

To simplify the analysis, we firstly collected the number of cases and controls from two groups (short and long) divided by the median telomere length for each study to evaluate the association. Because some studies reported data in three or five groups based on tertile or quintile value, we treated the groups of "Q1 and Q2" or "Q1, Q2 and Q3" as the short groups, respectively, and the other groups as the long groups. In the sensitivity analysis, we also performed analysis by dividing the subjects into three groups (short, medium and long). We combined Q2 and Q3 groups as the medium group for studies including four groups (Q1, Q2, Q3, Q4), and combined Q1 and Q2 groups as the short group, and Q4 and Q5 groups as the long group for studies including five groups (Q1, Q2, Q3, Q4, Q5). Two publications[@b29][@b47] providing the numbers of two groups only were excluded in this analysis. The association between the telomere length and cancer risk was examined by ORs and 95% CIs with the group of long telomeres as the reference. We performed cancer-specific analysis by cancer type and the cancer types reported in less than 3 studies were merged into the "other types of cancer" group. Gastrointestinal tumor included those diagnosed in the stomach, esophagus, colon or rectum. Cancers arising from the bladder, kidney and prostate sites were considered tumors of the urogenital system. We also performed analysis by study type (retrospective and prospective) and ethnicity (Caucasian, Asian or African American).

The χ^2^-based Q test was performed to evaluate between-study heterogeneity and considered significant if *P* \< 0.10[@b67]. Heterogeneity was also quantified with the *I*^2^ statistic that indicates what proportion of the total variation across studies is beyond chance. The value of 0% indicates no observed heterogeneity and larger values show increasing heterogeneity[@b68]. The fixed-effects model and the random-effects model were used to pool the data from different studies based on the Mantel-Haenszel method and the DerSimonian and Laird method, respectively[@b69].When the *P* value of the heterogeneity test was ≥0.10, the fixed-effects model was used, which assumes the homogeneity of effect size across all studies. Elsewise the random-effects model was more appropriate, which tends to provide wider confidence intervals, when the results of the constituent studies differ among themselves. Potential publication bias was evaluated with funnel plots of effect sizes versus standard errors. Begg's test was used to examine the significance of asymmetry at a significance value of 0.10. All analysis was conducted by using Review Manage (v.5.3) and R3.0.1.

Results
=======

Characteristics of Studies
--------------------------

A total of 56 publications were identified with an evaluation of the association between telomere length and cancer risk ([Fig. 1](#f1){ref-type="fig"}). Five reports were excluded because they did not provide the numbers of cases and controls grouped by the relative telomere length[@b62][@b63][@b64][@b65][@b66]. The remaining 51 publications contained 62 studies (Xifeng Wu's study[@b16] had datasets of four different cancers; Gabriella M. Anic's[@b11] and Jiali Han's[@b13] studies had three datasets of different cancers and Geyu Liang's[@b14], Beatriz Sanchez-Espiridion's[@b43], and Yang Zhang's[@b47] studies had two datasets of different cancers, and Jonathan N. Hofmann[@b21] had two datasets of independent populations. We summarized the general information of these 62 studies in [Table 1](#t1){ref-type="table"}. There were 10 studies for skin cancer[@b11][@b12][@b13][@b14][@b15] and tumors of urogenital system[@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23], 9 for gastrointestinal tumor[@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32], 8 for breast cancer[@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40] and lung cancer[@b16][@b41][@b42][@b43][@b44][@b45][@b46], 4 for head and neck cancer[@b16][@b47][@b48], 3 for lymphoma[@b49][@b50][@b51], and 10 for the other types of cancer with each type less than 3 studies[@b52][@b53][@b54][@b55][@b56][@b57][@b58][@b59][@b60][@b61] ([Table S1](#S1){ref-type="supplementary-material"}). Most of studies (n = 51) recruited subjects from populations of Caucasian descent, 10 studies of Asian descent, and one study of African American descent. The quantitative PCR was used to measure the relative telomere length (T/S ratio) in 55 studies, whereas fluorescence *in situ* hybridization (FISH)-based assays were used in 7 studies[@b16][@b39][@b45]. Additionally, blood cells were main DNA source except one study based on circulating cell-free serum DNA[@b54].

Quantitative Synthesis
----------------------

We obtained the telomere length data from 51 publications consisting of 23,379 cases and 68,792 controls. When pooling all eligible studies into the meta-analysis, we found a non-significant association between short telomeres and an increased risk of overall cancer risk (OR = 1.10, 95% CI: 0.98--1.23, [Table 2](#t2){ref-type="table"}). The directions of association were consistent among three populations from different descents (ORs = 1.08, 1.15 and 1.22 for Caucasian, Asian and African American, respectively, [Table 2](#t2){ref-type="table"}). The results of analysis for subgroups of different ethnicities have been shown in [Table S2](#S1){ref-type="supplementary-material"}. However, the association was disappeared in prospective studies (OR = 1.02, 95% CI: 0.87--1.19). Moreover, we also excluded three prospective studies[@b28][@b59][@b61] from the meta-analysis and found the similar results for overall cancer risk (OR = 1.07, 95% CI: 0.95--1.21).

Considering that heterogeneity is extensively occurred across cancer types, we then performed cancer-specific analysis ([Fig. 2](#f2){ref-type="fig"}). Short telomeres were significantly associated with increased risks of gastrointestinal tumor (OR = 1.62, 95% CI: 1.33--1.97) and head and neck cancer (OR = 1.86, 95% CI: 1.23--2.82). Of interest, in prospective studies rather than retrospective studies, short telomeres were associated with a decreased risk of lung cancer (OR = 0.78, 95% CI: 0.67--0.91). There was no obvious evidence supporting the association for the other cancer types ([Table 2](#t2){ref-type="table"}).

To evaluate the robustness of pooling results based on dichotomized telomere length, we further divided the cases and controls into three respective groups for each study, and tested the dose-response relationship between telomere length and cancer risk by pooling the studies together. We observed a significant increased risk of overall cancer for short telomeres with a trend OR (95% CI) of 1.09 (1.01--1.19) ([Table 3](#t3){ref-type="table"}). In cancer-specific analysis, dose-response effects of telomere length were also detected on gastrointestinal tumor (OR = 1.29, 95% CI: 1.08--1.54), and head and neck cancer (OR = 2.30, 95% CI: 1.74--3.02), which were consistent with the above results based on dichotomized telomere length ([Table 3](#t3){ref-type="table"}).

Heterogeneity analyses
----------------------

Substantial heterogeneity was observed among all studies for the association between telomere length and cancer risk (*P* \< 0.001, *I*^ 2^ = 90%, [Fig. 2](#f2){ref-type="fig"}). We then evaluated the potential source of heterogeneity and found significant effect difference between subgroups for cancer type (*P* \< 0.001), study design (*P* = 0.008), and ethnicity (*P* \< 0.001).

Publication bias
----------------

The shape of the funnel plot seemed symmetrical ([Fig. 3](#f3){ref-type="fig"}), and the Begg's test did not show a significant publication bias in the current meta-analysis (*P* = 0.142). These indicated that bias from publications might not have a significant influence on the results of our meta-analysis on the association between telomere length and cancer risk.

Discussion
==========

In this study, we performed the largest and most comprehensive literature review and meta-analysis on the association of telomere length and cancer risk, including a total of 23,379 cancer cases and 68,792 controls from 51 independent publications. We did not find significant association between telomere length and overall risk of cancers, but showed a robust association with gastrointestinal tumor and head and neck cancer. In addition, we also observed promising association of short telomeres with a decreased lung cancer risk in the prospective studies. Furthermore, dose-response relationships provided further evidence for the associations with gastrointestinal tumor, and head and neck cancer.

Telomeres are specialized structures that protect chromosome ends and participate in a number of processes of a great cellular relevance[@b70], which makes the telomere crucial in cellular senescence and carcinogenesis[@b71]. Progressive telomere shortening occurs with each cell division up to a point termed "replicative senescence" in most human somatic cells[@b72]. Basic biology studies have established that telomere shortening is a fundamental feature of dividing cells and directly related to the age of the cell lineage, and that telomere crisis in the present of defective cell-cycle control can lead to chromosomal instability and a malignant phenotype[@b73]. The dysfunctional telomeres will result in chromosomal fusions, continuous "breakage-fusion-bridge" cycles, derived chromosome imbalances, gene amplifications, and ultimately the generation of complex non-reciprocal translocations, a hallmark feature of adult solid tumors and genomic instability in general[@b74]. At the population level, the high incidence of cancer has prompted that shortening of telomeres promotes tumor development and several studies have found that patients with shorter telomeres in peripheral blood cells have a higher risk of developing carcinomas[@b75]. In this meta-analysis, although we found there is no significant association between telomere length and overall risk of cancers, but we demonstrated a significant association with gastrointestinal tumor and head and neck cancer, supporting the hypothesis that excessive telomere shortening may play an important role in accelerating tumor onset and progression. Gastrointestinal tumor and head and neck cancer is kind of epithelial malignancies in digestive system. The majority of epithelial malignancies appear to develop from morphologically defined precursor lesions termed intraepithelial neoplasia[@b76]. Telomere length in more than 90% intraepithelial neoplasia is dramatically shortened[@b77]. In addition, telomeres of gastrointestinal tumor may exhibit an intensified rate of shortening that is greatly accelerated as compared to the normal tissue of origin[@b78].

However, our results revealed heterogeneous association results between different cancer types. Short telomeres were convincingly associated with increased risk of gastrointestinal tumor and head and neck cancer, which, however, was not observed in other types of cancer. Of note, a significant but inverse association was shown for lung cancer in prospective studies. These inconsistent results across cancer types may reflect different carcinogenic mechanisms conferred by specific telomeres in specific cancer types. For example, several studies[@b11][@b12] found a higher risk for melanoma among individuals with longer telomeres, this may suggest that shorter telomere lengths protect against the malignant transformation of cells within melanocytic nevi by limiting proliferative capacity and triggering the entry to senescence stage. To the contrary, longer telomeres were found to be protective for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) with the reason of that UV exposure may be more likely to induce genomic abnormalities in cells with shorter telomeres. In addition, Sanchez-Espiridion *et al.*[@b43] found that patients with lung adenocarcinoma had longer telomeres than controls, whereas patients with lung squamous cell carcinoma had shorter telomeres compared with controls. These findings suggest that telomere length may affect cancer risk in a histologic manner, further highlighting the distinct roles of telomere in cancer development.

In addition to the cancer-specific associations, telomere length may also involve in cancer risk in a complex manner rather than a simple linear relationship. Cui *et al.*[@b25] reported a U-shaped association between telomere length in peripheral blood cells and colorectal cancer (CRC) risk, and they found that both very short and very long telomeres are risk factors for colorectal cancer. Recently, we also reported a non-linear relationship between telomeres and gastric cancer risk[@b28]. Similar results were also reported in pancreatic cancer[@b64], breast cancer[@b40] and glioma[@b66]. These observations are also biologically plausible because telomeres may act as a double-edged sword in the development of cancer. Telomere shortening can generally lead to chromosomal instability and finally initiate the process of carcinogenesis[@b16]. However, long telomeres may allow for more cell divisions and increase the chance of acquiring abnormalities for cancer development[@b79]. However, due to lack of original data, we cannot evaluate this phenomenon in this study. Further studies are warranted to carefully test these findings.

There are some limitations in this meta-analysis. Firstly, some factors can affect the length of telomeres, such as age, gender, and tobacco smoking, and oxidative stress[@b80][@b81]. The results of this meta-analysis were based on unadjusted estimates, because odds ratios (ORs) derived from different studies were not adjusted by the same potential confounders or only the number of cases and controls was provided without the detailed information of other variables. Secondly, we performed analysis by dividing the subjects into two or three groups simply due to lack of original data of relative telomere length, which may decrease the power to evaluate the relationship of telomere length and overall risk of cancers. In the main analysis of this study, we treated the groups of "Q1 and Q2" (for three groups) or "Q1, Q2 and Q3" (for five groups) as the short groups, and the other groups as the long groups. To address the stability of the results, we also treated the groups of "Q1" (for studies with three groups) or "Q1, and Q2" (for studies with five groups) as the short groups and the other groups as the long groups, and found that the results were similar (OR = 1.08, 95% CI: 0.96--1.22 for overall cancer risk).

In summary, our meta-analysis provided strong evidence for the association between short telomeres and increased risk of gastrointestinal tumor and head and neck cancer. In addition, the short telomeres also increased, although not significantly, the risk of overall cancer in the analysis of dichotomized variable, this association may be influenced by the study numbers of different tumors because the effects are different between tumors. However, larger, well-designed prospective studies are needed to validate these findings, which may help to uncover the potential mechanisms of telomere dysfunction in cancer development.
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###### Information summary of 51 eligible studies included in this meta-analysis.

  Author \[reference\]                                                      Country   Year                      Cancer type                          Ethnicity       No. of case/control    Study type             Control source                            DNA source                   Measurement methods
  ------------------------------------------------------------------------ --------- ------ ---------------------------------------------------- ------------------ --------------------- --------------- --------------------------------- -------------------------------------------- ---------------------
  Gabriella M. Anic *et al.*\_melonoma[@b11] [a](#t1-fn1){ref-type="fn"}      USA     2013                        melanoma                           Caucasian             198/372         retrospective           hospital-based                            leukocyte                     quantitative PCR
  Gabriella M. Anic *et al.*\_BCC[@b11] [a](#t1-fn1){ref-type="fn"}           USA     2013                  basal cell carcinoma                     Caucasian             185/372         retrospective           hospital-based                            leukocyte                     quantitative PCR
  Gabriella M. Anic *et al.*\_SCC[@b11] [a](#t1-fn1){ref-type="fn"}           USA     2013                squamous cell carcinoma                    Caucasian             136/372         retrospective           hospital-based                            leukocyte                     quantitative PCR
  Hongmei Nan *et al.*[@b12]                                                  USA     2011                   cutaneous melanoma                      Caucasian             557/579         retrospective          population-based                           leukocyte                     quantitative PCR
  Jiali Han *et al.*\_melonoma[@b13]                                          USA     2009                        melanoma                           Caucasian             204/222          prospective           population-based                           leukocyte                     quantitative PCR
  Jiali Han *et al.*\_SCC[@b13]                                               USA     2009                squamous cell carcinoma                    Caucasian             254/273          prospective           population-based                           leukocyte                     quantitative PCR
  Jiali Han *et al.*\_BCC[@b13]                                               USA     2009                  basal cell carcinoma                     Caucasian             282/306          prospective           population-based                           leukocyte                     quantitative PCR
  Geyu Liang *et al.*\_SCC[@b14]                                              USA     2011                squamous cell carcinoma                    Caucasian             241/241         retrospective          population-based                           leukocyte                     quantitative PCR
  Geyu Liang *et al.*\_BCC[@b14]                                              USA     2011                  basal cell carcinoma                     Caucasian            623/1943         retrospective          population-based                           leukocyte                     quantitative PCR
  Laura S. Burke *et al.*[@b15]                                               USA     2013                        melanoma                           Caucasian             119/208         retrospective            family-based             whole blood or EBV-transformed lymphocytes    quantitative PCR
  Xifeng Wu *et al.*\_RCC[@b16]                                               USA     2003                  renal cell carcinoma                     Caucasian              32/32          retrospective          population-based                           leukocyte                          Q-FISH
  Xifeng Wu *et al.*\_BLC[@b16]                                               USA     2003                     bladder cancer                        Caucasian             135/135         retrospective          population-based                           leukocyte                          Q-FISH
  Lisa Mirabello *et al.*[@b17]                                               USA     2009                    prostate cancer                        Caucasian            612/1049         retrospective          population-based                           leukocyte                     quantitative PCR
  B Julin *et al.*[@b18]                                                      USA     2015                    prostate cancer                        Caucasian             922/935         retrospective          population-based                           leukocyte                     quantitative PCR
  Lauren M. Hurwitz *et al.*[@b19]                                            USA     2014                    prostate cancer                        Caucasian             112/63          retrospective            family-based                             leukocyte                     quantitative PCR
  Jonathan N. Hofmann *et al.*[@b20]                                          USA     2013                  renal cell carcinoma                     Caucasian             209/410          prospective           population-based                           leukocyte                     quantitative PCR
  Jonathan N. Hofmann *et al.*\_Caucasian[@b21]                               USA     2011                  renal cell carcinoma                     Caucasian             658/550         retrospective          population-based                          whole blood                    quantitative PCR
  Jonathan N. Hofmann *et al.*\_African American[@b21]                        USA     2011                  renal cell carcinoma                  African American         233/344         retrospective          population-based                          whole blood                    quantitative PCR
  Monica McGrath *et al.*[@b22]                                               USA     2007                     bladder cancer                        Caucasian             184/192         retrospective          population-based                           leukocyte                     quantitative PCR
  Karin Broberg *et al.*[@b23]                                              Sweden    2005                     bladder cancer                        Caucasian              63/93          retrospective          population-based                          buccal cell                    quantitative PCR
  Andrew J. Pellatt *et al.*[@b24]                                            USA     2012                  colon rectal cancer                      Caucasian             525/746         retrospective          population-based                          whole blood                    quantitative PCR
  Yong Cui *et al.*[@b25]                                                    China    2012                   colorectal cancer                         Asian               512/549         retrospective          Population-based                           leukocyte                     quantitative PCR
  Qin Qin *et al.*[@b26]                                                     China    2014                   colorectal cancer                         Asian              628/1256         retrospective           hospital-based                            leukocyte                     quantitative PCR
  Lifang Hou *et al.*[@b27]                                                   USA     2009                     gastric cancer                        Caucasian             300/416         retrospective          population-based                           leukocyte                     quantitative PCR
  Rosa Ana Risques *et al.*[@b28]                                             USA     2007               esophageal adenocarcinoma                   Caucasian             38/300           prospective           population-based                           leukocyte                     quantitative PCR
  Qianqian Yu *et al.*[@b29]                                                 China    2014           esophageal squamous cell carcinoma                Asian               308/309         retrospective           hospital-based                            lymphocyte                    quantitative PCR
  Jiangbo Du *et al.*[@b30]                                                  China    2015                     gastric cancer                          Asian              1136/1102        retrospective          population-based                           leukocyte                     quantitative PCR
  Xiaonan Liu *et al.*[@b31]                                                 China    2009                     gastric cancer                          Asian               396/376         retrospective           hospital-based                            leukocyte                     quantitative PCR
  Jinliang Xing *et al.*[@b32]                                                USA     2009                   esophageal cancer                       Caucasian              94/92          retrospective           hospital-based                            leukocyte                     quantitative PCR
  Maria M. Gramatges *et al.*[@b33]                                           USA     2010                     breast cancer                         Caucasian             102/50          retrospective          population-based                           leukocyte                     quantitative PCR
  Andrew J. Pellatt *et al.*[@b34]                                            USA     2013                     breast cancer                         Caucasian             728/720         retrospective          population-based                           leukocyte                     quantitative PCR
  Jing Shen *et al.*[@b35]                                                    USA     2009                     breast cancer                         Caucasian            1026/1070        retrospective          population-based                           leukocyte                     quantitative PCR
  Immaculata *De Vivo et al.*[@b36]                                           USA     2009                     breast cancer                         Caucasian             896/917          prospective           population-based                           leukocyte                     quantitative PCR
  Sangmi Kim *et al.*[@b37]                                                   USA     2011                     breast cancer                         Caucasian             342/735          prospective           population-based                           leukocyte                     quantitative PCR
  Jing Shen *et al.*[@b38]                                                    USA     2007                     breast cancer                         Caucasian             283/347         retrospective            family-based                             leukocyte                     quantitative PCR
  Yun-Ling Zheng *et al.*[@b39]                                               USA     2010                     breast cancer                         Caucasian             292/335         retrospective          population-based                           leukocyte                          Q-FISH
  Shimian Qu *et al.*[@b40]                                                   USA     2012                     breast cancer                           Asian               601/695          prospective           population-based                           leukocyte                     quantitative PCR
  Xifeng Wu *et al.*\_LC[@b16]                                                USA     2003                      lung cancer                          Caucasian              54/54          retrospective          population-based                           leukocyte                          Q-FISH
  Min Shen *et al.*[@b41]                                                     USA     2011                      lung cancer                          Caucasian             230/229          prospective           population-based                           leukocyte                     quantitative PCR
  Qing Lan *et al.*[@b42]                                                     USA     2013                      lung cancer                            Asian               215/215          prospective           population-based                           leukocyte                     quantitative PCR
  Beatriz Sanchez-Espiridion *et al.*\_LAC[@b43]                              USA     2014                  lung adenocarcinoma                      Caucasian             706/706         retrospective           hospital-based                            leukocyte                     quantitative PCR
  Beatriz Sanchez-Espiridion *et al.*\_LSCC[@b43]                             USA     2014              lung squamous cell carcinoma                 Caucasian             320/320         retrospective           hospital-based                            leukocyte                     quantitative PCR
  Wei Jie Seow *et al.*[@b44]                                                 USA     2014                      lung cancer                          Caucasian             847/847          prospective           Population-based                           leukocyte                     quantitative PCR
  Bing Sun *et al.*[@b45]                                                     USA     2015                      lung cancer                          Caucasian             191/207         retrospective   Population-based hospital-based                   lymphocyte                         Q-FISH
  Jin Sung Jang *et al.*[@b46]                                               Korea    2008                      lung cancer                            Asian               243/243         retrospective           hospital-based                            leukocyte                     quantitative PCR
  Yang Zhang *et al.*\_OCC[@b47] [a](#t1-fn1){ref-type="fn"}                  USA     2013                   oral cavity cancer                      Caucasian             137/335         retrospective           hospital-based                            lymphocyte                    quantitative PCR
  Yang Zhang *et al.*\_OPC[@b47] [a](#t1-fn1){ref-type="fn"}                  USA     2013         oropharyngeal squamous cell carcinoma             Caucasian             188/335         retrospective           hospital-based                            lymphocyte                    quantitative PCR
  Da-Tian Bau *et al.*[@b48]                                                  USA     2013              oral squamous cell carcinoma                 Caucasian             92/394          retrospective           hospital-based                            leukocyte                     quantitative PCR
  Xifeng Wu *et al.*\_HNC[@b16]                                               USA     2003                  head and neck cancer                     Caucasian              92/92          retrospective          population-based                           leukocyte                          Q-FISH
  Qing Lan *et al.*[@b49]                                                     USA     2009                  non-Hodgkin lymphoma                     Caucasian             107/107         retrospective          population-based                           leukocyte                     quantitative PCR
  Fatemeh Saberi Hosnijeh *et al.*[@b50]                                     Iran     2014                    B-cell lymphoma                        Caucasian             414/414         retrospective          population-based                           leukocyte                     quantitative PCR
  Thomas A. Widmann *et al.*[@b51]                                          Germany   2007                 non-Hodgkin's lymphoma                    Caucasian              40/40          retrospective           hospital-based                            lymphocyte                        Flow-FISH
  Juan Liu *et al.*[@b52]                                                    China    2011   hepatitis B virus-related hepatocellular carcinoma        Asian               240/240         retrospective           hospital-based                            leukocyte                     quantitative PCR
  Shannon M. Lynch *et al.*[@b53]                                             USA     2013                   pancreatic cancer                       Caucasian             193/660          prospective           population-based                           leukocyte                     quantitative PCR
  Xiaoying Fu *et al.*[@b54]                                                  USA     2012                hepatocellular carcinoma                     Asian               140/280         retrospective           hospital-based                 circulating cell-free serum DNA          quantitative PCR
  Daniele Campa *et al.*[@b55]                                              Germany   2014                        myeloma                            Caucasian             140/468         retrospective          population-based                           leukocyte                     quantitative PCR
  Kathryn L. Terry *et al.*[@b56]                                             USA     2012                     ovarian cancer                        Caucasian             911/947         retrospective          population-based                           leukocyte                     quantitative PCR
  Farzana Walcott *et al.*[@b57]                                              USA     2013                         glioma                            Caucasian             101/198          prospective           population-based               blood, buffy coat, or buccal cells        quantitative PCR
  Jennifer Prescott *et al.*[@b58]                                            USA     2010                   endometrial cancer                      Caucasian             279/791          prospective           population-based                           leukocyte                     quantitative PCR
  Maren Weischer *et al.*[@b59]                                             Denmark   2013                         mixed                             Caucasian           3142/41169         prospective           Population-based                           leukocyte                     quantitative PCR
  Lisa Mirabello *et al.*[@b60]                                               USA     2009                     ovarian cancer                        Caucasian             99/100          retrospective          population-based                           leukocyte                     quantitative PCR
  Peter Willeit *et al.*[@b61]                                               Italy    2010                         mixed                             Caucasian             92/695           prospective           population-based                           leukocyte                     quantitative PCR

^a^The controls were shared for different cancer types in the same publication.

###### Summary of meta-analysis results for associations between telomere length and cancer risk.

  Groups                         Numbers   Heterogeneity   Associations (short vs. long)                             
  ----------------------------- --------- --------------- ------------------------------- ------ ------------------- ----------
  Overall                          62       23379/68792               \<0.001              0.90   1.10(0.98--1.23)      0.09
  Populations                                                                                                        
   Caucasian                       51       18727/63183               \<0.001              0.86   1.08(0.97--1.21)      0.18
   Asian                           10        4419/5265                \<0.001              0.95   1.15(0.78--1.68)      0.49
   African American                 1         233/344                   --                  --    1.22(0.88--1.71)      0.23
  Study design                                                                                                       
   Prospective                     16       7925/48662                \<0.001              0.82   1.02(0.87--1.19)      0.80
   Retrospective                   46       15454/20130               \<0.001              0.91   1.14(0.98--1.33)      0.10
  Skin cancer                                                                                                        
   Prospective                      3         740/801                  0.284               0.21   0.92(0.76--1.13)      0.44
   Retrospective                    7        2059/4087                \<0.001              0.94   1.36(0.82--2.24)      0.23
   Total                           10        2799/4888                \<0.001              0.91   1.17(0.83--1.66)      0.37
  Tumors of urogenital system                                                                                        
   Prospective                      1         209/410                   --                  --    0.92(0.66--1.28)      0.61
   Retrospective                    9        2951/3393                \<0.001              0.70   1.01(0.81--1.25)      0.95
   Total                           10        3160/3803                 0.002               0.66   0.99(0.82--1.20)      0.95
  Gastrointestinal tumor                                                                                             
   Prospective                      1         38/300                    --                  --    1.92(0.95--3.90)      0.07
   Retrospective                    8        3899/4846                \<0.001              0.80   1.60(1.30--1.97)    8.20E-06
   Total                            9        3937/5146                \<0.001              0.78   1.62(1.33--1.97)    2.03E-06
  Breast cancer                                                                                                      
   Prospective                      3        1839/2347                 0.370                0     1.13(0.99--1.28)      0.06
   Retrospective                    5        2431/2522                \<0.001              0.87   0.82(0.58--1.17)      0.28
   Total                            8        4270/4869                \<0.001              0.82   0.96(0.78-- 1.19)     0.70
  Lung cancer                                                                                                        
   Prospective                      3        1292/1291                 0.330               0.10   0.78(0.67--0.91)    1.69E-03
   Retrospective                    5        1514/1530                \<0.001              0.94   1.01(0.53--1.93)      0.97
   Total                            8        2806/2821                \<0.001              0.90   0.91(0.63--1.31)      0.60
  Head and neck cancer                                                                                               
   Prospective                     --                                                                                     
   Retrospective                    4        509/1156                  0.019               0.70   1.86(1.23--2.82)    3.50E-03
   Total                            4        509/1156                  0.019               0.70   1.86(1.23--2.82)    3.50E-03
  Lymphoma                                                                                                           
   Prospective                     --                                                                                     
   Retrospective                    3         561/561                 \<0.001              0.90   1.31(0.44--3.84)      0.63
   Total                            3         561/561                 \<0.001              0.90   1.31(0.44--3.84)      0.63
  Other types of cancer                                                                                              
   Prospective                      5       3807/43513                \<0.001              0.87   1.22(0.85--1.75)      0.29
   Retrospective                    5        1530/2035                \<0.001              0.95   0.69(0.33--1.45)      0.32
   Total                           10       5337/45548                \<0.001              0.94   0.92(0.64--1.32)      0.65

###### Dose-response relationship between telomere length and cancer risk by cancer type.

  Cancer type                    Numbers   Heterogeneity   Associations (short vs. medium vs. long)                            
  ----------------------------- --------- --------------- ------------------------------------------ ------ ------------------ ----------
  Overall                          59       22674/67727                    \<0.001                    0.91   1.09(1.01--1.19)    0.037
  Skin cancer                      10        2799/4888                     \<0.001                    0.94   1.11(0.83--1.49)    0.496
  Tumors of urogenital system      10        3160/3803                     \<0.001                    0.79   1.15(0.97--1.37)    0.113
  Gastrointestinal tumor            8        3558/4749                     \<0.001                    0.88   1.29(1.08--1.54)   4.24E-03
  Breast cancer                     8        4270/4869                     \<0.001                    0.83   0.96(0.83--1.11)    0.603
  Lung cancer                       8        2805/2823                     \<0.001                    0.90   1.11(0.86--1.42)    0.415
  Head and neck cancer              2         184/486                       0.284                     0.13   2.30(1.74--3.02)   2.85E-09
  Lymphoma                          3         561/561                      \<0.001                    0.87   0.99(0.53--1.83)    0.970

[^1]: These authors contributed equally to this work.
